Annual Meeting News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mirai Bio Presents Data Showing Rapid Advancement of Novel CD8+ T-Cell Targeted LNPs to Functional NHP Proof-of-Concept at ASGCT 2026...

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced proposals for its 2026 Annual General Meeting, including plans to appoint co-founder and former Chief Executive Officer Dr. Metin Colpan as Honorary Chairman, the continued renewal of the Supervisory Board and increased returns to shareholders. The Annual General Meeting, to be held on June 24, 2026, in Venlo, the Netherlands, will include proposals to elect Robert McMahon as a new member of...

LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it will hold its annual shareholders’ meeting (“AGM”) on June 3rd, 2026, at 10:00 am, at the offices of Jones Day, Hotel de Talleyrand, 2 rue Saint Florentin, 75001 Paris. The notice of this shareholders’ meeting, which se...

LYON, France--(BUSINESS WIRE)--MaaT Pharma to Hold Annual General Meeting on June 16, 2026...

CHICAGO--(BUSINESS WIRE)--As the global magnetic resonance (MR) community convenes for the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE HealthCare (Nasdaq: GEHC) today announced advancements in research tools and MR systems that aim to accelerate discovery, strengthen collaboration across research programs, and turn innovation into meaningful clinical achievements. GE HealthCare continues to invest in advanced MR technology with its next-generation SI...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, and provided an operational update on botensilimab plus balstilimab (BOT+BAL), the Company’s lead clinical program and one of the most clinically advanced next-generation CTLA-4/PD-1 combinations in development. The first quarter marked a transition from foundation-building to execution for BOT+BAL. Physician engageme...

BEIJING & SHANGHAI--(BUSINESS WIRE)--Therorna presents circRNA-based in vivo CAR-T, T-cell engager, and therapeutic cancer vaccine data at ASGCT 2026 in Boston....

TORONTO--(BUSINESS WIRE)--Sherritt International Corporation (“Sherritt” or the “Corporation”) (TSX:S) provides the following updates further to its May 7, 2026 news release regarding the Executive Order issued by the U.S. administration on May 1, 2026 expanding its sanctions against Cuba. Sherritt plans to issue a notice of application today in the Ontario Superior Court of Justice, Commercial List, under which Sherritt plans to seek (i) a compliance order under the Canada Business Corporation...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs) following progression after standard first-line therapy. epNECs are an aggressive mal...

CALGARY, Alberta--(BUSINESS WIRE)--Pembina Pipeline Corporation ("Pembina" or the "Company") (TSX: PPL; NYSE: PBA) reported the voting results from its annual meeting of shareholders held virtually on May 8, 2026 (the "Meeting"). Each of the matters voted upon at the Meeting is discussed in detail in the Company's Management Information Circular dated March 19, 2026 (the "Information Circular"), which is available on SEDAR+ at www.sedarplus.ca, on EDGAR at www.sec.gov, and on the Company's webs...